Terms: = Kidney tumors AND SETD2, ENSG00000181555, 29072 AND Clinical Outcome
5 results:
1. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract] [Full Text] [Related]
2. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract] [Full Text] [Related]
3. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
Chen YB; Xu J; Skanderup AJ; Dong Y; Brannon AR; Wang L; Won HH; Wang PI; Nanjangud GJ; Jungbluth AA; Li W; Ojeda V; Hakimi AA; Voss MH; Schultz N; Motzer RJ; Russo P; Cheng EH; Giancotti FG; Lee W; Berger MF; Tickoo SK; Reuter VE; Hsieh JJ
Nat Commun; 2016 Oct; 7():13131. PubMed ID: 27713405
[TBL] [Abstract] [Full Text] [Related]
4. Decreased Expression of setd2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
[TBL] [Abstract] [Full Text] [Related]
5. clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract] [Full Text] [Related]